The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations
CompletedOBSERVATIONAL
Enrollment
513
Participants
Timeline
Start Date
July 31, 2005
Primary Completion Date
September 30, 2007
Study Completion Date
March 31, 2015
Conditions
Antiphospholipid Syndrome
Trial Locations (1)
30029
CHU de Nîmes - Hôpital Universitaire Carémea, Nîmes
All Listed Sponsors
lead
Centre Hospitalier Universitaire de Nīmes
OTHER
NCT02855047 - The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations | Biotech Hunter | Biotech Hunter